Q4 2025 Genomma Lab Internacional SAB de CV Earnings Call Transcript
Key Points
- Genomma Lab Internacional SAB de CV (GNMLF) achieved a resilient year-end EBITDA margin of 23.4%, highlighting strong operational efficiency and cost management.
- The company unlocked over MXN1 billion in productivity savings, which are being reinvested into growth initiatives for 2026.
- Despite a challenging year, Genomma Lab maintained a conservative balance sheet with a net debt-to-EBITDA ratio of just 1.1 times.
- The company plans to expand its distribution network significantly, aiming to increase coverage from 730,000 to 860,000 points of sales by 2026.
- Genomma Lab is increasing its media spend by 28% and diversifying its media strategy to include more digital and out-of-home formats, aiming for more efficient and effective marketing.
- Genomma Lab faced a challenging year in 2025 with a 5.7% decline in consolidated net sales, largely due to a deliberate reduction in Mexico sell-in to normalize retailer inventories.
- The Mexican market experienced a significant downturn, with full-year sell-in declining by 7% and a 22.1% decline in Q4.
- The isotonic beverage category saw a market contraction of 5% in 2025, impacting Genomma Lab's sales projections.
- The company lost market share in the skin care and beverage categories, with a notable 1-point loss in the beverage market share.
- Genomma Lab's net income declined by 23% year-on-year, primarily due to higher non-cash ForEx losses linked to the Argentine peso depreciation.
Good day, ladies and gentlemen. Thank you for joining Genomma Lab's fourth-quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this meeting is being recorded and will be available for replay from the Investor Relations section of Genomma's website following the call. I'll now turn the call over to Christianne Ibanez, Genomma's Head of Investor Relations. Please go ahead.
± -
Thank you, and welcome, everyone. On today's call are Marco Sparvieri, Chief Executive Officer; and Antonio Zamora, Chief Financial Officer.
Before we get started, I'd like to remind you that the remarks today will include forward-looking statements such as the company's financial guidance and expectations, including long-term objectives and forecasts as well as expectations regarding Genomma's business, products, strategies, demand, and markets. These statements are subject to risks and uncertainties that could cause actual results to differ materially. They
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
